Original ResearchEditorial CommentIntensive Blood Pressure Management to Prevent Stroke
Editorial Comment
Section snippets
Funding Support and Author Disclosures
Dr Chow has received support from a National Health and Medical Research Council investigator grant and speakers’ fees on cardiovascular disease prevention from AbbVie, AstraZeneca, Amgen, Eli Lilly, Novartis, Novo Nordisk, National Heart Foundation, and is on the boards of the National Heart Foundation and the Western Sydney Local Health District. Dr O’Hagan has reported that she has no relationships relevant to the contents of this paper to disclose.
References (10)
- J. Li et al.
Effect of intensive blood pressure control on stroke: a prespecified secondary analysis of the ESPRIT trial
JACC
(2025) - R. Trivedi et al.
Factors influencing blood pressure control in patients with atrial fibrillation and hypertension in Australian primary care
Heart
(2023) - J. Yue et al.
Comparing secondary prevention for patients with coronary heart disease and stroke attending Australian general practices: a cross-sectional study using nationwide electronic database
BMJ Qual Saf
(2024) - P.K. Whelton et al.
Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis
Hypertension
(2024) - A. Albasri et al.
Association between antihypertensive treatment and adverse events: systematic review and meta-analysis
BMJ
(2021)
There are more references available in the full text version of this article.
Cited by (0)
- The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2025 Published by Elsevier on behalf of the American College of Cardiology Foundation